Adjuvant Capital

Adjuvant Capital is a distinctive venture capital firm dedicated to improving global health by financing promising life science technologies that address high-burden public health challenges. The firm focuses on historically overlooked market segments, leveraging its expertise to generate both social and financial returns for its investors. Its mission is to deploy venture capital strategies to advance public health technologies and ensure their accessibility to those who need them most, particularly in low- and middle-income countries.

Founded in 2018 by Glenn Rockman and Charlie Petty, Adjuvant Capital emerged with a clear vision to bridge the gap in life sciences investment within emerging economies. The firm's investment strategy prioritizes opportunities that have demonstrated human efficacy, typically from Phase II or later clinical trials, and seeks compelling proof-of-concept data to support its decisions. Adjuvant Capital manages $300 million in assets under management, as of September 30, 2023, and is backed by leading strategic investors and alternative asset managers, including the Bill & Melinda Gates Foundation, Novartis, and the International Finance Corporation.

Adjuvant Capital's portfolio includes investments in companies developing innovative solutions for a range of critical health issues. Notable portfolio companies include VitriVax, Univercells, Codagenix, and Themis (which was acquired by Merck). The firm also supports companies like Excision BioTherapeutics, which focuses on CRISPR-based therapies for chronic viral infectious diseases, and Memo Therapeutics, an antibody discovery platform. Other investments target areas such as next-generation subunit vaccines (Curevo Vaccine), Group B Streptococcal vaccines (MinervaX), and novel therapies for respiratory diseases (Pulmocide).

The Adjuvant team is comprised of experienced venture capital and private equity investors, global public health leaders, disease-specific technical experts, and pharmaceutical industry veterans. This diverse expertise, coupled with deep ties to the global health community and long-standing relationships with major funders, is integral to the firm's investment sourcing and execution process. Key team members include Co-Founders and Partners Glenn Rockman and Kabeer Aziz, along with a robust group of partners, associates, and senior advisors across their New York and Zurich offices.